DMRA
DMRA
KYG2646Y1044
Damora Therapeutics, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue -- --
--
Cost of Revenue -- --
--
Gross Profit -- --
--
210.872.000 21.292.000
890.4%
Operating Income -210.872.000 -21.292.000
890.4%
Pretax Income -209.789.000 -21.398.000
880.4%
Net Income Common Stockholders -209.839.000 -21.439.000
878.8%
-- --
--
-- --
--
ende